# Surgical Treatment for Spinal Scoliosis in Patient With Mitochondrial Disease After Heart Transplantation: A Case Report and Literature Review

**Authors:** Shintaro Abe, Masayuki Miyagi, Wataru Saito, Ryo Tamaki, Tomohisa Inoue, Kenji Hagiwara, Gen Inoue, Ken Okazaki, Masashi Takaso

PMC · DOI: 10.1155/cro/8814759 · Case Reports in Orthopedics · 2026-03-04

## TL;DR

This case report describes the first successful scoliosis surgery in a patient with mitochondrial disease after a heart transplant, highlighting the need for strict management during such procedures.

## Contribution

The first reported case of scoliosis surgery in a mitochondrial disease patient post-heart transplantation.

## Key findings

- Scoliosis surgery was successfully performed with strict management of intravascular volume and lactic acidosis.
- Spinal correction and fusion were achieved and maintained for 2 years post-surgery.
- The case demonstrates that minimally invasive techniques can meet surgical goals without compromising outcomes.

## Abstract

We present an extremely rare case of scoliosis surgery for mitochondrial disease after heart transplantation.

An 18‐year‐old female patient with mitochondrial disease underwent heart transplantation for dilated cardiomyopathy at age 12. After heart transplantation, she presented with progressive scoliosis with a Cobb angle of 101°. Therefore, we performed spinal correction and fusion surgery under strict management. Postoperative spinal radiography revealed successful spinal correction and maintained correction 2 years after surgery.

This is the first report of scoliosis surgery in a patient with mitochondrial disease after heart transplantation. Scoliosis surgery in patients after heart transplantation requires strict management of the circulating intravascular volume, because the denervated heart is preload‐dependent. Moreover, patients with mitochondrial disease should be treated for lactic acidosis caused by surgical stress and perioperative electrolyte abnormalities. Our case showed successful performance in minimizing invasiveness without compromising the surgical goals of correction and fusion.

## Linked entities

- **Diseases:** mitochondrial disease (MONDO:0004069), dilated cardiomyopathy (MONDO:0005021), scoliosis (MONDO:0005392)

## Full-text entities

- **Genes:** TOP3A (DNA topoisomerase III alpha) [NCBI Gene 7156] {aka MGRISCE2, PEOB5, TOP3, ZGRF7}
- **Diseases:** psychiatric symptoms (MESH:D001523), Muscle weakness (MESH:D018908), diabetes (MESH:D003920), lactic acidosis (MESH:D000140), blood loss (MESH:D016063), intrauterine growth retardation (MESH:D005317), short stature (MESH:D006130), Mitochondrial Disease (MESH:D028361), spinal deformity (MESH:D013122), seizures (MESH:D012640), hypoxia (MESH:D000860), restrictive ventilatory impairment (MESH:D012131), bleeding (MESH:D006470), cardiomyopathy (MESH:D009202), fatigue (MESH:D005221), pneumonia (MESH:D011014), infection (MESH:D007239), dilated cardiomyopathy (MESH:D002311), hypoglycemia (MESH:D007003), end-stage dilated cardiomyopathy (MESH:D007676), ischemic stroke (MESH:D002544), hemiparesis (MESH:D010291), hypovolemia (MESH:D020896), congenital heart disease (MESH:D006330), Scoliosis (MESH:D012600), hypothermia (MESH:D007035), epilepsy (MESH:D004827), thrombosis (MESH:D013927), blood (MESH:D006402), migraines (MESH:D008881), sinus tachycardia (MESH:D013616), heart disease (MESH:D006331)
- **Chemicals:** propofol (MESH:D015742), remifentanil (MESH:D000077208), fentanyl (MESH:D005283)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12958027/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12958027/full.md

## References

16 references — full list in the complete paper: https://tomesphere.com/paper/PMC12958027/full.md

---
Source: https://tomesphere.com/paper/PMC12958027